These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9089667)

  • 1. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats.
    Kalkman HO; Neumann V; Tricklebank MD
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):361-4. PubMed ID: 9089667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats.
    Ahlqvist J; Isacson R; Wahlestedt C; Salmi P
    Eur Neuropsychopharmacol; 2003 May; 13(3):177-82. PubMed ID: 12729943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat.
    Kalkman HO; Neumann V; Hoyer D; Tricklebank MD
    Br J Pharmacol; 1998 Aug; 124(7):1550-6. PubMed ID: 9723970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
    Ninan I; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential.
    Bartoszyk GD; Roos C; Ziegler H
    Neuropharmacology; 1996; 35(11):1645-6. PubMed ID: 9025114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.
    Oerther S; Ahlenius S
    J Pharmacol Exp Ther; 2000 Feb; 292(2):731-6. PubMed ID: 10640312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity.
    Farber NB; Foster J; Duhan NL; Olney JW
    Schizophr Res; 1996 Jul; 21(1):33-7. PubMed ID: 8998274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similarity of clozapine's and olanzapine's acute effects on rats' lapping behavior.
    Das S; Fowler SC
    Psychopharmacology (Berl); 1996 Feb; 123(4):374-8. PubMed ID: 8867877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate.
    Jardemark KE; Liang X; Arvanov V; Wang RY
    Neuroscience; 2000; 100(1):1-9. PubMed ID: 10996453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
    Verma A; Kulkarni SK
    Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine.
    Fujimura M; Hashimoto K; Yamagami K
    Eur J Pharmacol; 2000 Jun; 398(1):1-10. PubMed ID: 10856442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalepsy induced by SCH 23390 in rats.
    Morelli M; Di Chiara G
    Eur J Pharmacol; 1985 Nov; 117(2):179-85. PubMed ID: 2866970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.
    Ninan I; Jardemark KE; Wang RY
    Neuropharmacology; 2003 Mar; 44(4):462-72. PubMed ID: 12646283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats.
    Ahnaou A; Megens AA; Drinkenburg WH
    Neuropsychobiology; 2003; 48(1):47-54. PubMed ID: 12886041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine.
    Ninan I; Kulkarni SK
    Eur J Pharmacol; 1999 Feb; 368(1):1-7. PubMed ID: 10096763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine.
    Porter JH; Strong SE
    Psychopharmacology (Berl); 1996 Nov; 128(2):216-9. PubMed ID: 8956383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain.
    Timmerman W; Heijmen M; Westerink BH; Bruggeman R; den Boer JA
    Psychopharmacology (Berl); 1999 Jun; 144(3):286-94. PubMed ID: 10435397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of olanzapine on cognitive functions and catalepsy in rats after single and chronic administration.
    Nowakowska E; Chodera A; Kus K
    Pol J Pharmacol; 1999; 51(4):295-300. PubMed ID: 10540960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats.
    Ortega-Alvaro A; Gibert-Rahola J; Micó JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):104-11. PubMed ID: 16226364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral pharmacology of olanzapine: a novel antipsychotic drug.
    Moore NA; Leander JD; Benvenga MJ; Gleason SD; Shannon H
    J Clin Psychiatry; 1997; 58 Suppl 10():37-44. PubMed ID: 9265915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.